Dosage research on Tesamorelin

Preclinical research dose ranges

In published preclinical research on Tesamorelin and on the broader GHRH-analogue family, administered dose ranges in rodent studies have most commonly fallen in the 1 to 100 microgram per kilogram range delivered subcutaneously. Pharmacology characterising the stabilised-GHRH-analogue activation of the GHRH receptor and downstream GH-pulse generation has used doses in this range across rat and mouse studies.

The pharmacokinetic studies characterising the stabilised-analogue half-life (extended relative to native GHRH(1-44) through the addition of a trans-3-hexenoic acid modification at the N-terminus) have used single-bolus subcutaneous administration in the microgram-per-kilogram range. The N-terminal modification is what gives Tesamorelin its protease resistance and extended plasma persistence relative to native GHRH.

Body-composition and visceral-adipose-tissue endpoints in animal models have used doses in a comparable range across multi-week protocols. The pharmacology rationale for the FDA-approved HIV-associated lipodystrophy indication traces back to body-composition effects characterised in this preclinical and clinical body of work.

Clinical trial dose ranges

The published clinical-trial literature on Tesamorelin has tested specific dose levels in HIV-associated lipodystrophy contexts. The registration trials (Falutz and colleagues 2007, 2008) tested 2 mg subcutaneously once daily. The 2 mg daily dose became the FDA-approved dose. Subsequent investigator-initiated work has tested doses across a comparable range in other body-composition and metabolic-endpoint contexts.

These doses are reported here as published clinical-trial doses, not as recommendations. Tesamorelin is FDA-approved as a human therapeutic under a separate brand name that the Ronin catalog does not market; clinical use occurs under licensed prescriber care at doses determined by the prescriber, not by reference to research-reagent vials.

Dose-response considerations from the published literature

The published Tesamorelin clinical-trial literature has reported dose-response characteristics across the registration trials and subsequent investigator-initiated work. Visceral-adipose-tissue reduction and IGF-I elevation scaled with dose across the tested range in the lipodystrophy population. The cross-trial dose comparisons in body-composition endpoints have not converged on a single canonical dose-response curve because of population heterogeneity across trials.

Preclinical dose-response work has shown effects scaling with dose across the 1 to 100 microgram per kilogram rodent range on GH-pulse amplitude and IGF-I time-course endpoints. The cross-species dose-translation depends on the pharmacokinetic differences between rodent and human and on the endpoint being measured.

Reconstitution math and per-vial dose calculation

A 10 mg lyophilised Tesamorelin vial reconstituted with 2 mL of bacteriostatic water yields a stock concentration of 5 mg per mL. From this stock, a research aliquot of 0.4 mL contains 2 milligrams (matching the FDA-approved daily clinical dose if dosing on a per-vial basis is desired for comparator-arm research replication). An aliquot of 0.1 mL contains 500 micrograms. Researchers working with rodent pharmacology dose ranges further dilute the stock to a working concentration appropriate to the model and the body weight of the animal subject. Refrigerated storage at 2 to 8 degrees Celsius, protected from light, is the standard handling practice.

Research-protocol design considerations

Protocol-design choices in the published Tesamorelin literature reflect several recurring considerations. Clinical-trial dose selection anchors at the 2 mg daily subcutaneous dose for the registration and subsequent body-composition-endpoint trials. Preclinical dose selection anchors at the 1 to 100 microgram per kilogram range subcutaneously in rodent models.

Route of administration in both clinical and preclinical work is overwhelmingly subcutaneous. Daily dosing in clinical work reflects the pharmacokinetics of the stabilised-GHRH-analogue; some investigator-initiated work has explored alternative dosing cadences but the registration data is daily.

The stabilised-GHRH-analogue mechanism is the primary protocol-design consideration in any comparison with other GHRH-axis tools (sermorelin / native GHRH(1-29), CJC-1295 No DAC / modified GHRH(1-29), CJC-1295 with DAC). The trans-3-hexenoic acid N-terminal modification provides protease resistance and extended plasma persistence relative to native GHRH, which gives Tesamorelin a longer functional duration per dose than sermorelin.

References

1. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007. [PMID 18046025]
2. Falutz J et al. Effects of tesamorelin on visceral fat in HIV. New England Journal of Medicine, 2008. [PMID 18768934]
3. Stanley TL et al. Effects of tesamorelin on visceral adipose tissue and cardiometabolic parameters in HIV-infected patients with abdominal fat accumulation. Journal of Clinical Endocrinology and Metabolism, 2014. [PMID 24438373]
4. Falutz J et al. Long-term safety and effects of tesamorelin in HIV-infected patients with abdominal fat accumulation. AIDS, 2008. [PMID 18594276]
5. Stanley TL et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV. Lancet HIV, 2019. [PMID 31578259]
6. Adrian S et al. The growth hormone releasing hormone analogue tesamorelin in HIV-associated lipodystrophy. Expert Review of Endocrinology and Metabolism, 2019. [PMID 31380682]